conference call......
IDE filed for Adcon-A
filed to initiate use of -L in breast
initiated pivotal -P trials
record revenue for quarter, 7.9 million
solid quarter in Europe
gross margin 85%
Board authorized share buyback, 250K shares
14.5% penetration (lumbar, single-level procedures, total market approx. 400K procedures/year), April weak, immediate strong comeback in May and June, record sales in June
1575 hospitals, out of initial targeted 2000
strong reorder rate of >90%
reoperation positive experiences reported
positive economic data published (see this thread)
international Adcon sales up 58%, year over year
3 gram syringe complements 5 gram syringe, addresses price sensitivity in Europe
expect approval for -L in Japan by end of year, expect to file on -T/N within same time frame
phase I multiple dose rising study for 2331 completed, results to be reported in September. Partnership discussions ongoing.
awaiting, as usual, word from Janssen regarding choice of a preclinical candidate (geeeeeeeeeeeeeeeeeze)
humanizing anti-properdin
Q&A....
no inventory stocking in pharmacies (duh!).
price holding firm.
July off to a good start.
18% penetration still the target for year.
research funding from Janssen terminating.
expect more reports (publications) regarding reoperations.
company fields questions regarding -L for other indications, such as breast augmentation, tethered cord and frozen shoulder.
(Harry Tracy!)
3 gram syringe coming to U.S., probably not this year.
begin first part of August to hit hospital compensation managers with pharmacoeconomic data.
phase IIa with 2331..... actively planning study, committed to filing, still may rely on partner depending on how discussions go, but sites and investigators chosen, first investigator meeting next week, trial could commence as early as fourth quarter.
not aware of any competition for -L, in clinic or otherwise. |
